Sahm Adrangi is a well-known man in the investing world thanks to his many accomplishments as an investor and his success at Kerrisdale Capital. This private investment firm invests in various companies around the world. Today, being able to identify quality companies in the stock market is a challenge, and Sahm Adrangi is standing out where not many can. Kerrisdale has managed to excel and come out on top of the S&P 500 for several successive quarters.
On a normal basis, Kerrisdale Capital puts out reports on various companies in the market, and their latest was quite the negative report against biotech firm Proteostasis. This biotech company is home to Cambridge and has recently been making claims of a new breakthrough in terms of cystic fibrosis. Their new drug in development, PTI-428, is aimed at helping increasing lung performance in patients.
Unfortunately for Proteostasis, Kerrisdale was not impressed with their figures and the data they released, so Sahm Adrangi decided to do a little more digging into the company. Upon even closer examination of the results of the company, their actual test sample was extremely small. So small in fact, PTI-428 was only tested on four patients. This is not nearly enough to make such claims the company has been making, causing their company stock value to go up.
We short (misguided) innovation for a living, but shorting bitcoin or doubting cryptocurrencies is nutty. The mkt opportunity is massive https://t.co/Q4vsI9nuyf
— Sahm Adrangi (@SahmAdrangi) September 25, 2017
Kerrisdale took quickly to their report to get it out as soon as possible to inform the public and many investors out there of what is really behind this biotech company, Proteostasis. According to Sahm Adrangi, their drug cocktail is most likely an ineffective drug that works better as a placebo. Unfortunately for Proteostasis, the majority of their company value is invested in their product, which means they will lose more than 70% of their company share value when it comes out that PTI-428 is not effective.
As more companies and investors are becoming aware of the nature of this biotech company, their share values continue to drop and will likely push the company off the map in the near future.
SWball April 19, 2018